Lithium interaction with sulindac and naproxen.
The interaction of lithium with sulindac and naproxen was studied in six sulindac-treated and seven naproxen-treated patients admitted to a geropsychiatry ward. Patients under a steady state lithium level received lithium for 3 days, then lithium + sulindac (300 mg/day) or naproxen (750 mg/day) for 6 days, and then lithium alone for 5 days. Sulindac failed to affect serum lithium levels and lithium clearance. The results with naproxen showed marked interindividual variations ranging from no increase to a 41.9% increase in serum lithium levels within 5 days. There was a corresponding decrease in lithium clearance in naproxen-treated patients. Patients undergoing lithium therapy might need a reduction of their lithium dosage following naproxen administration. More frequent serum lithium level determinations are required following initiation of naproxen therapy until the magnitude of the lithium-naproxen drug interaction can be adequately assessed in a given individual.
M
M
Ragheb
A L
AL
Powell
D000368:Aged; D004347:Drug Interactions; D006801:Humans; D007192:Indenes / Q000009:adverse effects*; D008094:Lithium / Q000097:blood*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects*; D013467:Sulindac / Q000009:adverse effects*
D007192:Indenes; D013467:Sulindac; D009288:Naproxen; D008094:Lithium